Suppr超能文献

肝门空肠吻合术:采用新型辅助治疗方案的12年经验

Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen.

作者信息

Stringer Mark D, Davison Suzanne M, Rajwal Sanjay R, McClean Patricia

机构信息

St. James's University Hospital, Leeds LS9 7TF, UK.

出版信息

J Pediatr Surg. 2007 Aug;42(8):1324-8. doi: 10.1016/j.jpedsurg.2007.03.026.

Abstract

AIM

The role of adjuvant therapy with corticosteroids and choleretics after Kasai portoenterostomy for biliary atresia (BA) remains uncertain. Experience with a novel postoperative adjuvant therapy regimen is reported.

METHODS

Between 1994 and 2006, 71 infants with BA were referred. Four died from uncorrectable congenital heart disease/cardiorespiratory failure without undergoing portoenterostomy, 7 underwent primary liver transplantation (3 referred > or = 19 weeks of age), and 60 underwent portoenterostomy at a median of 51 (10-104) days. Of these, 55 (92%) had type 3 BA and 6 had the BA splenic malformation syndrome. Fifty (83%) received the following adjuvant therapy beginning on postoperative day 5: oral dexamethasone 0.3 mg/kg bd for 5 days, 0.2 mg/kg bd for 5 days, and 0.1 mg/kg bd for 5 days together with oral ursodeoxycholic acid 5 mg/kg bd and phenobarbitone 5 mg/kg nocte, both of which were continued for 1 year. All infants received routine perioperative prophylactic antibiotics.

RESULTS

Overall, 42 of 60 (70%) infants cleared their jaundice (bilirubin < 20 micromol/L): 38 of 50 (76%) with the dexamethasone/ursodeoxycholic acid regimen compared with 4 of 10 (40%) not receiving this adjuvant treatment. There were 4 late deaths after portoenterostomy: 2 from associated congenital disorders and 2 after liver transplantation. Of the remaining 56 children, 39 (70%) are currently alive with their native liver at a median follow-up of 3.3 years and 17 are alive after liver transplantation. Surgical complications occurred in 3 after portoenterostomy: adhesive bowel obstruction (2) and an anastomotic leak. One infant had gastrointestinal bleeding that may have been related to dexamethasone, but this resolved with ranitidine. There were no perioperative septic complications.

CONCLUSION

In this series, adjuvant postoperative treatment with a short course of oral dexamethasone and longer-term ursodeoxycholic acid significantly improved the outcome after Kasai portoenterostomy.

摘要

目的

在胆管闭锁(BA)的Kasai肝门空肠吻合术后,使用皮质类固醇和利胆剂进行辅助治疗的作用仍不明确。本文报告了一种新型术后辅助治疗方案的经验。

方法

1994年至2006年间,收治了71例BA患儿。4例因无法纠正的先天性心脏病/心肺衰竭未接受肝门空肠吻合术而死亡,7例行原位肝移植(3例转诊时年龄≥19周),60例行肝门空肠吻合术,中位年龄为51(10 - 104)天。其中,55例(92%)为3型BA,6例患有BA脾畸形综合征。50例(83%)患儿术后第5天开始接受以下辅助治疗:口服地塞米松0.3mg/kg,每日2次,共5天;0.2mg/kg,每日2次,共5天;0.1mg/kg,每日2次,共5天,同时口服熊去氧胆酸5mg/kg,每日2次,苯巴比妥5mg/kg,每晚1次,两种药物均持续使用1年。所有患儿均接受围手术期常规预防性抗生素治疗。

结果

总体而言(60例中),42例(70%)患儿黄疸消退(胆红素<20μmol/L):接受地塞米松/熊去氧胆酸方案的50例中有38例(76%),未接受该辅助治疗的10例中有4例(40%)。肝门空肠吻合术后有4例晚期死亡:2例死于相关先天性疾病,2例死于肝移植后。其余56例患儿中,39例(70%)目前存活,自体肝中位随访时间为3.3年,17例肝移植后存活。肝门空肠吻合术后3例出现手术并发症:粘连性肠梗阻(2例)和吻合口漏。1例患儿出现可能与地塞米松有关的胃肠道出血,但使用雷尼替丁后出血停止。围手术期无感染性并发症。

结论

在本系列研究中,短期口服地塞米松和长期使用熊去氧胆酸进行术后辅助治疗显著改善了Kasai肝门空肠吻合术后的结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验